Medicine and HealthCell Death and Disease
A broad neutralizing nanobody against SARS-CoV-2 engineered from an approved drug
Q. Liu, Y. Lu, et al.
Discover VHH60, a groundbreaking neutralizing nanobody that competes with human ACE2 to inhibit SARS-CoV-2 infection. Developed by an expert team, this nanobody shows superior protective capabilities against both ancestral and variant strains, showcasing a rapid approach to therapeutic innovation.
Related Publications
Explore these studies to deepen your understanding
Adjacent work that informs or extends this paper's methodology and findings.
Medicine and Health
A Gamma-adapted subunit vaccine induces broadly neutralizing antibodies against SARS-CoV-2 variants and protects mice from infection
L. M. Coria, J. M. Rodriguez, et al.
Medicine and Health
Immunogenicity and protection of a variant nanoparticle vaccine that confers broad neutralization against SARS-CoV-2 variants
J. Logue, R. M. Johnson, et al.
Medicine and Health
A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants
Y. Du, R. Shi, et al.
Medicine and Health
A bispecific nanobody dimer broadly neutralizes SARS-CoV-1 & 2 variants of concern and offers substantial protection against Omicron via low-dose intranasal administration
H. Ma, X. Zhang, et al.
